{"id":401,"date":"2012-07-26T11:43:07","date_gmt":"2012-07-26T06:13:07","guid":{"rendered":"https:\/\/old.anandandanand.com\/oldupdates\/?p=401"},"modified":"2016-09-28T11:44:49","modified_gmt":"2016-09-28T06:14:49","slug":"a-step-into-the-unknown-indias-first-compulsory-licence","status":"publish","type":"post","link":"https:\/\/old.anandandanand.com\/oldupdates\/a-step-into-the-unknown-indias-first-compulsory-licence\/","title":{"rendered":"A Step into the Unknown: India\u2019s First Compulsory Licence"},"content":{"rendered":"<p><em>Archana Shanker considers the implications of the grant of a compulsory licence for the very first time in the Indian patent system.<\/em><\/p>\n<p>The licence was granted to Natco Pharma, a generic drug company, for sorafenib tosylate, a life-extending drug developed, patented and launched by Bayer Corporation. This drug is sold under the trade name of Nexavar and is used for the treatment of advanced-stage kidney and liver cancer.<\/p>\n<p>The Controller General of Patents has set a benchmark in this landmark decision by invoking Section 84(1), a crucial provision of the Indian Patents Act which allows any person interested to file an application for grant of compulsory licence on a patent at any time from three years after grant on various grounds mentioned in the Indian Patents Act.<\/p>\n<p><em>This article was published in Life Sciences Intellectual Property Review 2012.<\/em><\/p>\n<p>To continue reading, please contact us at <a href=\"mailto:email@anandandanand.com\">email@anandandanand.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Archana Shanker considers the implications of the grant of a compulsory licence for the very first time in the Indian patent system. The licence was granted to Natco Pharma, a generic drug company, for sorafenib tosylate, a life-extending drug developed, patented and launched by Bayer Corporation. This drug is sold under the trade name of [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11],"tags":[58,57],"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/old.anandandanand.com\/oldupdates\/wp-json\/wp\/v2\/posts\/401"}],"collection":[{"href":"https:\/\/old.anandandanand.com\/oldupdates\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/old.anandandanand.com\/oldupdates\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/old.anandandanand.com\/oldupdates\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/old.anandandanand.com\/oldupdates\/wp-json\/wp\/v2\/comments?post=401"}],"version-history":[{"count":2,"href":"https:\/\/old.anandandanand.com\/oldupdates\/wp-json\/wp\/v2\/posts\/401\/revisions"}],"predecessor-version":[{"id":403,"href":"https:\/\/old.anandandanand.com\/oldupdates\/wp-json\/wp\/v2\/posts\/401\/revisions\/403"}],"wp:attachment":[{"href":"https:\/\/old.anandandanand.com\/oldupdates\/wp-json\/wp\/v2\/media?parent=401"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/old.anandandanand.com\/oldupdates\/wp-json\/wp\/v2\/categories?post=401"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/old.anandandanand.com\/oldupdates\/wp-json\/wp\/v2\/tags?post=401"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}